This summary of $5 1 0 ( \mathsf { k } )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is K133411

# SUBMITTER

Alere Scarborough, Inc.   
10 Southgate Road   
Scarborough, ME 04074   
Establishment Registration Number: 1221359   
CONTACT PERSON   
Angela Drysdale   
(207) 730-5737 (0ffice)   
(207) 730-5767 (FAX)   
Angela.drysdale@alere.com (email)

# DATE PREPARED

TRADE NAME Alere BinaxNOw® Influenza A & B Card

COMMON NAME Not Applicable

# CLASSIFICATION NAME

Influenza virus serological reagents (per 21 CFR 866.3330)

CLASSIFICATION Class 1

PRODUCT CODE GNX

PANEL Microbiology

PREDICATE DEVICE Alere BinaxNOW® Influenza A & B Card, K092223

# DEVICE DESCRIPTION

The Alere BinaxNOw® Influenza A & B Card is an immunochromatographic membrane assay that uses highly sensitive monoclonal antibodies to detect influenza type A and B nucleoprotein antigens in respiratory specimens. These antibodies and a control antibody are immobilized onto a membrane support as three distinct lines and combined with other reagents/pads to construct a test strip. This test strip is mounted inside a cardboard, book-shaped hinged test card.

Swab sees requea ampe preparation , in whic he sample is eluthe wab into luion soluon, salne r tranort meiNasal wash/aspirate sample requie o preparation. Sampl is  t the  te t ip ndhe tet cr i cos Te esul e ed  miu bas e ur  l.

# INTENDED USE

The Alere BinaxNOW $\otimes$ Influenza A & B Card is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab, nasal swab, and nasal was/aspirate eens.It s ntened t iinhe apid difeential digoss o inflenza A and i infeons.Negative test results are presumptive and should be confrmed by cell culture or n A-ceared inluenza A and B molecular assay. Negative test results do not preclude influenza viral infection and hould not be used as the sole basis for treatment or other patient management decisions.

Caution: Assay sensitivity or nasal wash/aspirate samples was determined primarily using archived spemens.   
Users may wish to establish the sensitivity of these specimens on fresh samples.

# COMPARISON TO THE PREDICATE

The Alere BinaxNOw® Influenza A & B Card, under consideration in this special ${ \bf 5 1 0 ( k ) }$ filing is exactly the same test as the currently 510(k) cleared Alere BinaxNOw® Influenza A & B Card, there have been no moications to the test; the fundamental scientiic technology of the test has not been altered.Both use lateral flow immunochromatographic technology. Both tests are rapid immunoassays that employ specific antibodies immobilized onto solid phases to capture and visualize influenza nucleoprotein antigens.

# PERFORMANCE SUMMARY

The clinical performance of the Alere BinaxNow® Influenza A & B Card was established in multi-center, v  su u  l o he  00 seaon and at three US tril sites during the 200-2006 repiratory eason.Additional performance test was conucted on retrospective rozen clinical samples collected from symptomatic patients at multiple physician o ciic and hospia ocat in he South Northeaste nMiestegins he Unt ae and from one hospital in Sweden.

# Clinical Studies:

Alere BinaxNOw® Influenza A & B Card Performance vs. Cell Culture / DFA - Prospective Study lf 846 prospeive spemes collecd from childre ess than 8 years  gend adults 18 years olr were evaluated in the Alere BinaxNOw® Influenza A & B Card and compared to culture/DFA. Evaluated specimens include nasopharyngeal and nasal swabs collected from patients presenting with influenza-like symptoms. Forty-four percent $( 4 4 \% )$ of the population tested was male, $5 6 \%$ female, $5 4 \%$ pediatric $( < 1 8$ years), and $4 6 \%$ adult $\{ \ge 1 8$ years). No differences in test performance were observed based on patient age or gender. $A / \mathsf { H } 3$ and $A / \mathbb { H } 1$ were the predominant influenza subtypes observed during this time.

Alere BinaxNOw® Influenza A & B Card performance by sample type versus cell culture / DFA, including $9 5 \%$ confidence intervals, is listed below.

# Alere BinaxNOw® Influenza A & B Card Performance vs. Cell Culture/DFA for Detection of Flu A

<table><tr><td rowspan=1 colspan=5>Test Sensitivity</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>+/+</td><td rowspan=1 colspan=1>-/+</td><td rowspan=1 colspan=1>% Sens</td><td rowspan=1 colspan=1>95% Cl</td></tr><tr><td rowspan=1 colspan=1>NP Swab</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>77%</td><td rowspan=1 colspan=1>65-86%</td></tr><tr><td rowspan=1 colspan=1>Nasal Swab</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>83%</td><td rowspan=1 colspan=1>74-90%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>138</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>81%</td><td rowspan=1 colspan=1>74-86%</td></tr></table>

<table><tr><td rowspan=1 colspan=5>Test Specificity</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>-1</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>% Spec</td><td rowspan=1 colspan=1>95% Cl</td></tr><tr><td rowspan=1 colspan=1>NP Swab</td><td rowspan=1 colspan=1>278</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>99%</td><td rowspan=1 colspan=1>97-100%</td></tr><tr><td rowspan=1 colspan=1>Nasal Swab</td><td rowspan=1 colspan=1>378</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>96%</td><td rowspan=1 colspan=1>93-96%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>656</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>96-98%</td></tr></table>

# Alere BinaxNOw® Influenza A & B Card Performance vs. Cell Culture/DFA for Detection of Flu B

<table><tr><td rowspan=1 colspan=5>Test Sensitivity</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>+/+</td><td rowspan=1 colspan=1>-/+</td><td rowspan=1 colspan=1>% Sens</td><td rowspan=1 colspan=1>95% Cl</td></tr><tr><td rowspan=1 colspan=1>NP Swab</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>9-91%</td></tr><tr><td rowspan=1 colspan=1>Nasal Swab</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>69%</td><td rowspan=1 colspan=1>39-90%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>65%</td><td rowspan=1 colspan=1>39-85%</td></tr></table>

<table><tr><td rowspan=1 colspan=5>Test Specificity</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>-/</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>% Spec</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>NP Swab</td><td rowspan=1 colspan=1>346</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>99-100%</td></tr><tr><td rowspan=1 colspan=1>Nasal Swab</td><td rowspan=1 colspan=1>481</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>98-100%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>827</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>99-100%</td></tr></table>

# Alere BinaxNOw® Influenza A & B Card Performance vs. Cell Culture / DFA - Retrospective Study

A total of 293 retrospective frozen clinical samples were evaluated in the BinaxNOw $\circledast$ Influenza A & B Test and compared to culture/DFA. All clinical samples were collected from symptomatic patients at multiple physician offices, clinics and hospitals located in the Southern, Northeastern and Midwestern regions of the United States and from one hospital in Sweden. Fifty-three percent $( 5 3 \% )$ of the population tested was male, $4 7 \%$ female, $6 2 \%$ pediatric $\cdot < 1 8$ yearsand $3 8 \%$ adult $\mathord { \left\{ \ge \ 1 8 \right. } $ years). Nasal wash/aspirate specimens comprised approximately $6 1 \%$ of the samples tested, while NP swabs represented $3 9 \%$ .No differences in test performance were observed based on patient age and gender or based on sample type tested.

ler BinaxNOw® Influenza A & B Card performance by sample type versus cell culture / DFA, including $9 5 \%$ onfidence intervals, is listed below.

Alere BinaxNOw® Influenza A & B Card Performance vs. Cell Culture/DFA for Detection of Flu A   

<table><tr><td rowspan=1 colspan=5>Test Sensitivity</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>+/+</td><td rowspan=1 colspan=1>-/+</td><td rowspan=1 colspan=1>% Sens</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>NP Swab</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>70%</td><td rowspan=1 colspan=1>50-86%</td></tr><tr><td rowspan=1 colspan=1>Wash/Aspirate</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>89%</td><td rowspan=1 colspan=1>78-96%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>83%</td><td rowspan=1 colspan=1>73-90%</td></tr></table>

Alere BinaxNOw® Influenza A & B Card Performance vs. Cell Culture/DFA for Detection of Flu B   

<table><tr><td rowspan=1 colspan=5>Test Specificity</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>/</td><td rowspan=1 colspan=1>+/-</td><td rowspan=1 colspan=1>% Spec</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>NP Swab</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>90%</td><td rowspan=1 colspan=1>81-95%</td></tr><tr><td rowspan=1 colspan=1>Wash/Aspirate</td><td rowspan=1 colspan=1>117</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>89-98%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>194</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>93%</td><td rowspan=1 colspan=1>88-96%</td></tr></table>

<table><tr><td colspan="5" rowspan="1">Test Sensitivity</td></tr><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">+/+</td><td colspan="1" rowspan="1">-1+</td><td colspan="1" rowspan="1">% Sens</td><td colspan="1" rowspan="1">95% CI</td></tr><tr><td colspan="1" rowspan="1">NP Swab</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">Wash/Aspirate</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">53%</td><td colspan="1" rowspan="1">27-78%</td></tr><tr><td colspan="1" rowspan="1">Overall</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">53%</td><td colspan="1" rowspan="1">27-78%</td></tr><tr><td colspan="5" rowspan="1">Test Specificity</td></tr><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">+1-</td><td colspan="1" rowspan="1">% Spec</td><td colspan="1" rowspan="1">95% CI</td></tr><tr><td colspan="1" rowspan="1">NP Swab</td><td colspan="1" rowspan="1">111</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">98%</td><td colspan="1" rowspan="1">93-100%</td></tr><tr><td colspan="1" rowspan="1">Wash/Aspirate</td><td colspan="1" rowspan="1">155</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">94%</td><td colspan="1" rowspan="1">89-97%</td></tr><tr><td colspan="1" rowspan="1">Overall</td><td colspan="1" rowspan="1">266</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">96%</td><td colspan="1" rowspan="1">92-98%</td></tr></table>

# Analytical Sensitivity:

The Alere BinaxNOw® Influenza A &B Card limi ofdetection (LOD), defined as the concetration infuza virus that produces positive Alere BinaxNOw® Influenza A & B Card results approximately $9 5 \%$ of the time, was identified by evaluating different concentrations of inactivated Flu A/Beijing and inactivated Flu B/Harbin in the Alere BinaxNOw® Influenza A $\&$ B Card.

Twelve different operators cach interpreted two cards run at each concentration for a total of 24 determinations per level. The following results identify a concentration of $1 . 0 3 \times 1 0 ^ { 2 } \mathrm { n g / m l }$ as the LOD for Flu A/Beijing and $6 . 0 5 \times 1 0 ^ { 1 } \mathrm { n g / m l }$ for Flu B/Harbin.

<table><tr><td rowspan=1 colspan=3>Flu A/Beijing</td></tr><tr><td rowspan=1 colspan=1>Concentration (ng/ml)</td><td rowspan=1 colspan=1># Detected</td><td rowspan=1 colspan=1>% Detected</td></tr><tr><td rowspan=1 colspan=1>1.03 x 10² (LOD)</td><td rowspan=1 colspan=1>23/24</td><td rowspan=1 colspan=1>96</td></tr><tr><td rowspan=1 colspan=1>5.60 x 101 (Cutoff)</td><td rowspan=1 colspan=1>*</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>3.27 x 101 (High Neg)</td><td rowspan=1 colspan=1>4/24</td><td rowspan=1 colspan=1>17</td></tr><tr><td rowspan=1 colspan=1>True Negative</td><td rowspan=1 colspan=1>0/24</td><td rowspan=1 colspan=1>0</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Flu B/Harbin</td></tr><tr><td rowspan=1 colspan=1>Concentration (ng/ml)</td><td rowspan=1 colspan=1># Detected</td><td rowspan=1 colspan=1>% Detected</td></tr><tr><td rowspan=1 colspan=1>6.05x101(LOD)</td><td rowspan=1 colspan=1>23/24</td><td rowspan=1 colspan=1>96</td></tr><tr><td rowspan=1 colspan=1>2.42 x 101(Cutoff)</td><td rowspan=1 colspan=1>11/24</td><td rowspan=1 colspan=1>46</td></tr><tr><td rowspan=1 colspan=1>1.51 x 101 (High Neg)</td><td rowspan=1 colspan=1>6/24</td><td rowspan=1 colspan=1>25</td></tr><tr><td rowspan=1 colspan=1>True Negative</td><td rowspan=1 colspan=1>0/24</td><td rowspan=1 colspan=1>0</td></tr></table>

\*Linr rressn was us to calculate a le equatin, whic was hen usd to project the cutoconcenan of Flu A/Beijing.

# Analytical Reactivity:

The influenza A and B strains listed tested positive in the Alere BinaxNow® Influenza A & B Card at conntrations speci Althouh the speciinfluenza strais causig infecion in huans can varyro year to year, all contain the conserved nucleoproteins targeted by the Alere BinaxNOw® Influenza A & B Card. Performance characteristics of the Alere BinaxNOw® Influenza A & B Card for detecting influenza A virus from human specimens was established when H1 and H3 subtypes were prevalent. Performance characteristics of the test when other influenza A virus subtypes aremerging as human pathogens have not been established.

<table><tr><td colspan="1" rowspan="1">Influenza Strain</td><td colspan="1" rowspan="1">ATCC #</td><td colspan="1" rowspan="1">Concentration</td></tr><tr><td colspan="1" rowspan="1">Flu A/WS/33 (H1N1)</td><td colspan="1" rowspan="1">VR-825</td><td colspan="1" rowspan="1">102-106 CEIDso/ml</td></tr><tr><td colspan="1" rowspan="1">Flu A/NWS/33 (H1N1)</td><td colspan="1" rowspan="1">VR-219</td><td colspan="1" rowspan="1">102-106 CEID5o/ml</td></tr><tr><td colspan="1" rowspan="1">Flu A/Hong Kong/8/68 (H3N2)</td><td colspan="1" rowspan="1">VR-544</td><td colspan="1" rowspan="1">102-106 CEID5o/ml</td></tr><tr><td colspan="1" rowspan="1">Flu A/Aichi/2/68 (H3N2)</td><td colspan="1" rowspan="1">VR-547</td><td colspan="1" rowspan="1">102-106 CEID50/ml</td></tr><tr><td colspan="1" rowspan="1">Flu A/New Jersey /8/76 (Hsw1N1)</td><td colspan="1" rowspan="1">VR-897</td><td colspan="1" rowspan="1">102-106 CEIDso/ml</td></tr><tr><td colspan="1" rowspan="1">Flu A/Mal/302/54 (H1N1)</td><td colspan="1" rowspan="1">VR-98</td><td colspan="1" rowspan="1">102-106 CEIDso/ml</td></tr><tr><td colspan="1" rowspan="1">Flu A/Port Chalmers/1/73 (H3N2)</td><td colspan="1" rowspan="1">VR-810</td><td colspan="1" rowspan="1">102-106 CEID50/ml</td></tr><tr><td colspan="1" rowspan="1">Flu A/Hong Kong/156/97 (H5N1)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1.3 x 10² TCIDso/ml</td></tr><tr><td colspan="1" rowspan="1">Flu A/Vietnam/1194/04 (H5N1)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1.0 x 104 TCIDso/ml</td></tr><tr><td colspan="1" rowspan="1">Flu A/California/04/2009 (H1N1) swl(swine lineage)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">5.63 x 104 TCIDso/ml</td></tr><tr><td colspan="1" rowspan="1">Flu A/Auckland/1/2009 A(H1N1) swl</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1.0 x 105 TC1D50/ml</td></tr><tr><td colspan="1" rowspan="1">Flu A/Auckland/3/2009 A(H1N1) swl</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1.0 x 105 TC1D50/ml</td></tr><tr><td colspan="1" rowspan="1">Flu A/Chicken/NY/117228-7/01 (H5N2)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1.0 x 104 EID5o/ml</td></tr><tr><td colspan="1" rowspan="1">Flu A/Turkey/VA/SEP-66/02 (H7N2)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1.0 x 105 ElDso/ml</td></tr><tr><td colspan="1" rowspan="1">Flu A/A/ANHUI/1/2013 (H7N9)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1.94 x 106 EID50/ml</td></tr><tr><td colspan="1" rowspan="1">Flu B/Lee/40</td><td colspan="1" rowspan="1">VR-101</td><td colspan="1" rowspan="1">102-106 CEIDso/ml</td></tr><tr><td colspan="1" rowspan="1">Flu B/Brigit</td><td colspan="1" rowspan="1">VR-786</td><td colspan="1" rowspan="1">102-106 CEID50/ml</td></tr><tr><td colspan="1" rowspan="1">Flu B/Russia/69</td><td colspan="1" rowspan="1">VR-790</td><td colspan="1" rowspan="1">102-106 CEIDso/ml</td></tr><tr><td colspan="1" rowspan="1">Flu B/Hong Kong/5/72</td><td colspan="1" rowspan="1">VR-791</td><td colspan="1" rowspan="1">102-106 CE1D50/ml</td></tr><tr><td colspan="1" rowspan="1">Flu B/R75</td><td colspan="1" rowspan="1">VR-789</td><td colspan="1" rowspan="1">102-106 CEIDso/ml</td></tr></table>

Although this test has been shown to detect the Flu A/California/04/2009 (H1N1) and Flu A/Anhui/1/2013 (H79) viruses cultured from positive human specimens, the performance characteristics of this card with human specimens infected with these two influenza viruses have not been established The Alere BinaxNow Inuenza A &B Card can stiguish betwefuenza A and viruse, but it does ot diffentite al influenza A virus from influenza A 2009 H1N1 or influenza A H7N9. The ability to detect human infection with the 2009 H1N1 or H7N9 influenza virus in clinical specimens is unknown.

# Analytical Specificity (Cross-Reactivity):

To determine the analytical specificity of the Alere BinaxNOw® Influenza A & B Card, 36 commensal and pathogenic microorganisms (27 bacteria, 8 viruses and 1 yeast) that may be present in the nasal cavity or nasopharynx were tested. All of the following microorganisms were negative when tested at concentrations ranging from $1 0 ^ { 4 }$ to $1 0 ^ { 8 } ~ \mathrm { T C I D } _ { 5 0 } / \mathrm { m l }$ (viruses), $1 0 ^ { 7 }$ to $1 0 ^ { 8 }$ organisms $\mathbf { \dot { m } } \mathbf { l }$ (bacteria) and $1 0 ^ { 6 }$ organisms/ml (yeast).

<table><tr><td colspan="1" rowspan="1">Bacteria</td><td colspan="1" rowspan="1">Viruses</td><td colspan="1" rowspan="1">Yeast        •</td></tr><tr><td colspan="1" rowspan="1">Acinetobacter</td><td colspan="1" rowspan="1">Adenovirus</td><td colspan="1" rowspan="1">Candida albicans</td></tr><tr><td colspan="1" rowspan="1">Bordetella pertussis</td><td colspan="1" rowspan="1">Coronavirus</td><td colspan="1" rowspan="20"></td></tr><tr><td colspan="1" rowspan="1">Enterococcus faecalis</td><td colspan="1" rowspan="1">Coxsackie B4</td></tr><tr><td colspan="1" rowspan="1">Escherichia coli</td><td colspan="1" rowspan="1">Cytomegalovirus (CMV)</td></tr><tr><td colspan="1" rowspan="1">Gardnerella vaginalis</td><td colspan="1" rowspan="1">Parainfluenza 1</td></tr><tr><td colspan="1" rowspan="1">Haemophilus influenzae</td><td colspan="1" rowspan="1">Parainfluenza 2</td></tr><tr><td colspan="1" rowspan="1">Klebsiella pneumoniae</td><td colspan="1" rowspan="1">Parainfluenza 3</td></tr><tr><td colspan="1" rowspan="1">Lactobacillus casei</td><td colspan="1" rowspan="1">Respiratory Syncytial Virus (RSV)</td></tr><tr><td colspan="1" rowspan="1">Legionella pncumophila</td><td colspan="1" rowspan="13"></td></tr><tr><td colspan="1" rowspan="1">Listeria monocytogenes</td></tr><tr><td colspan="1" rowspan="1">Moraxella catarrhalis</td></tr><tr><td colspan="1" rowspan="1">Neisseria gonorrhoeae</td></tr><tr><td colspan="1" rowspan="1">Neisseria meningitidis</td></tr><tr><td colspan="1" rowspan="1">Neisseria sicca</td></tr><tr><td colspan="1" rowspan="1">Neisseria subflava</td></tr><tr><td colspan="1" rowspan="1">Proteus vulgaris</td></tr><tr><td colspan="1" rowspan="1">Pseudomonas aeruginosa</td></tr><tr><td colspan="1" rowspan="1">Serratia marcescens</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus aureus</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus aureus(Cowan protein A producingstrain</td></tr><tr><td colspan="1" rowspan="1">Staphylococcus epidermidis</td></tr><tr><td colspan="1" rowspan="1">Bacteria</td><td colspan="1" rowspan="1">Viruses</td><td colspan="1" rowspan="1">Yeast</td></tr><tr><td colspan="1" rowspan="1">Streptococcus, Group A</td><td colspan="1" rowspan="6"></td><td colspan="1" rowspan="6"></td></tr><tr><td colspan="1" rowspan="1">Streptococcus, Group B</td></tr><tr><td colspan="1" rowspan="1">Streptococcus, Group C</td></tr><tr><td colspan="1" rowspan="1">Streptococcus, Group F</td></tr><tr><td colspan="1" rowspan="1">Streptococcus mutans</td></tr><tr><td colspan="1" rowspan="1">Streptococcus pneumoniae</td></tr></table>

# Interfering Substances:

The followig substancs, naturaly preent in respiratoryseciens or that may be artificalintrucd into the nasal cavity or nasopharynx, were evaluated in the Alere BinaxNOw® Influenza A $\&$ B Card at the concentrations listed and were found not to affect test performance. Whole blood $( 1 \% )$ did not interfere with the interpretation of negative Alere BinaxNOw® Influenza A & B Card results, but did interfere with the interpretation of Flu A LOD positive samples. Therefore, visibly bloody samples may not be appropriate for use in this test.

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Concentration</td></tr><tr><td rowspan=1 colspan=1>1 OTC mouthwash</td><td rowspan=1 colspan=1>20%</td></tr><tr><td rowspan=1 colspan=1>3 OTC nasal sprays</td><td rowspan=1 colspan=1>15%</td></tr><tr><td rowspan=1 colspan=1>3 OTC throat drops</td><td rowspan=1 colspan=1>15%</td></tr><tr><td rowspan=1 colspan=1>2 OTC throat sprays</td><td rowspan=1 colspan=1>20%</td></tr><tr><td rowspan=1 colspan=1>4-acetamidophenol</td><td rowspan=1 colspan=1>10 mg/ml</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>15 mg/ml</td></tr><tr><td rowspan=1 colspan=1>Albuterol</td><td rowspan=1 colspan=1>20 mg/ml</td></tr><tr><td rowspan=1 colspan=1>Chlorpheniramine</td><td rowspan=1 colspan=1>5 mg/ml</td></tr><tr><td rowspan=1 colspan=1>Dextromethorphan</td><td rowspan=1 colspan=1>10 mg/ml</td></tr><tr><td rowspan=1 colspan=1>Diphenhydramine</td><td rowspan=1 colspan=1>5 mg/ml</td></tr><tr><td rowspan=1 colspan=1>Guaiacol glycerol ether</td><td rowspan=1 colspan=1>20 mg/ml</td></tr><tr><td rowspan=1 colspan=1>Oxymetazoline</td><td rowspan=1 colspan=1>0.05%</td></tr><tr><td rowspan=1 colspan=1>Phenylephrine</td><td rowspan=1 colspan=1>50 mg/ml</td></tr><tr><td rowspan=1 colspan=1>Pheny/propanolamine</td><td rowspan=1 colspan=1>20 mg/ml</td></tr><tr><td rowspan=1 colspan=1>Rebetol®</td><td rowspan=1 colspan=1>500 ng/ml</td></tr><tr><td rowspan=1 colspan=1>Relenza®</td><td rowspan=1 colspan=1>20 mg/ml</td></tr><tr><td rowspan=1 colspan=1>Rimantadine</td><td rowspan=1 colspan=1>500 ng/ml</td></tr><tr><td rowspan=1 colspan=1>Synagis®</td><td rowspan=1 colspan=1>0.1 mg/ml</td></tr><tr><td rowspan=1 colspan=1>Tamiflu®</td><td rowspan=1 colspan=1>50 mg/ml</td></tr></table>

# Reproducibility Study:

A blind study of the Alere BinaxNOw® Influenza A & B Card was conducted at 3 separate sites using panels blind coded specimens containing negative, low positive, and moderate positive samples. Participants tested each sample multiple times on 3 different days. There was $9 7 \%$ (242/250) agreement with expected test results, with no significant differences within run (replicates tested by one operator), between run (3 different days), between sites (3 sites), or between operators (6 operators).

Signed Angela Drysdale.

# VP Regulatory and Clinical Affairs - Infectious Disease Alere Scarborough, Inc.

ALERE SCARBOROUGH INC.   
ANGELA DRYSDALE   
VP OF REGULATORY AND CLINICAL AFFAIRS - INFECTIOUS DISEASE I0 SOUTHGATE ROAD   
SCARBOROUGH ME 04074

December 5, 2013

Re: K133411 Trade/Device Name: Alere BinaxNOw" Intluenza A & B Card Regulation Number: 21 CFR 866.3330 Regulation Name: Influenza virus serological reagents Regulatory Class: 1 Product Code: GNX Dated: November 5. 2013 Reccived: November 7. 2013

Dear Ms. Drysdale:

We have reviewed your Section $5 1 0 ( k )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28. 1976. the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmctic Act (Act) that do nol require approval of a premarkel approval application (PMA). You may. therefore. market the device. subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices. good manufacturing practice. labeling. and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you. however, that device labeling must be truthful and not misleading.

1f your devicc is classified (sec above) into cither class 11 (Special Controls) or class 11 (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition. FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complics with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements. including. but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Parts 801 and 809): medical device reporting (reporting of medical device-related adverse events) (21 CFR 803): good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Pan 820): and if applicable. thc electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809). please contact the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://wwv.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htum. Also. please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803). please go t0   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Officc of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http:/www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

# Uwe Scherf -S for

Sally Hojvat. M.Se.. Ph.D)   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostics and Radiological   
Health   
Center for Devices and Radiological Health

# Indications For Use

510(k) Number (if known): K133411

# Device Name: Alere BinaxNOW® Influenza A & B Card

Intended Use: The Alere BinaxNOW® Influenza A & B Card is an in vitro immunochromatographic assay for the qualitative detection of influenza A and 8 nucleoprotein antigens in nasopharyngeal (NP) swab, nasal swab, and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results are presumptive and should be confirmed by cell culture or an FDA-cleared influenza A and B molecular assay. Negative test results do not preclude influenza viral infection and should not be used as the sole basis for treatment or other patient management decisions.

Caution: Assay sensitivity for nasal wash/aspirate samples was determined primarily using archived specimens. Users may wish to establish the sensitivity of these specimens on fresh samples.

Prescription Use_ (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of Center for Devices and Radiological Health (CDRH)

Li Li -S